The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

J Allergy Clin Immunol Pract. 2021 May;9(5):1805-1812. doi: 10.1016/j.jaip.2021.02.035. Epub 2021 Mar 1.

Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.

Keywords: ARIA; Allergic rhinitis; EAACI; Immunotherapy; mHealth.

MeSH terms

  • Asthma* / diagnosis
  • Asthma* / therapy
  • Desensitization, Immunologic
  • Humans
  • Rhinitis, Allergic* / diagnosis
  • Rhinitis, Allergic* / therapy
  • Telemedicine*